NAYA Biosciences, Inc.

NAYA Biosciences, Inc. focuses on developing clinical and commercial-stage assets for fertility, oncology, and autoimmune diseases. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma; and NY-338, a CD38-targeted FLEX-NK bispecific antibody for multiple myeloma and autoimmune diseases. The company also offers INVOcell, an IVC device that is an alternative to IVF that uses the female body for fertilization and incubation. The company was formerly known as and changed its name to is based in Sarasota, Florida.